Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for core social symptoms in children with autism spectrum disorder
IRCT20260324069012N1Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in Autism Spectrum Disorder (ASD), sponsored by Mashhad University of Medical Sciences. Started Apr 2026; status: recruiting.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20260324069012N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260324069012N1.